No Data
BioMarin Pharmaceutical Sues Ascendis Pharma for Patent Infringement in Germany
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading
Evercore ISI Remains a Buy on Ascendis Pharma (ASND)
Wells Fargo Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $289
This Coca-Cola Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Ascendis Pharma Initiated at Buy by UBS